Journey Medical Corporation Announces Data From Bioavailability Study Of DFD-29 Vs. Solodyn
Portfolio Pulse from Benzinga Newsdesk
Journey Medical Corporation (NASDAQ:DERM) announced data from a comparative bioavailability study of DFD-29 vs. Solodyn. The study demonstrated that the systemic exposure of DFD-29 was significantly lower than that of Solodyn. The company plans to submit a New Drug Application to the FDA for DFD-29 in the fourth quarter of 2023. DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy's Laboratories Ltd.
October 20, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the bioavailability study of DFD-29 could potentially boost Journey Medical's stock in the short term as it indicates progress in the company's drug development pipeline.
The announcement of positive results from a drug study is typically viewed as a positive development for a pharmaceutical company. This could potentially lead to increased investor confidence in the company's ability to successfully develop and commercialize new drugs, which could in turn lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100